on October 6, 2005
Published online before print October 6, 2005, doi: 10.1161/01.ATV.0000189309.05924.88
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 16, 2005
Accepted on September 23, 2005
Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans
James J. Oliver *;
From Centre for Cardiovascular Science (J.J.O., D.J.W., D.E.N.), University of Edinburgh, Edinburgh, UK.
* To whom correspondence should be addressed. E-mail: James.Oliver{at}ed.ac.uk.
Abstract--The initiation, modulation, and resolution of thrombus associated with eroded or unstable coronary plaques are critically dependent on the efficacy of endogenous fibrinolysis. This is dependent on the cellular function of the surrounding endothelium and vascular wall. In particular, the acute release of tissue plasminogen activator from the endothelium makes an important contribution to the defense against intravascular thrombosis. Here, we describe the rationale and methodology for, and clinical relevance of, assessing acute endothelial tissue plasminogen activator release in humans. The investigation of endothelial fibrinolytic function has the potential to provide major new insights into the pathophysiology of cardiovascular disease, and to shape future therapeutic interventions.
This article has been cited by other articles:
 |
|
 |
|
  C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway Hypertension, August 1, 2008; 52(2): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Lang, I. J. Guthmundsdottir, N. A. Boon, C. A. Ludlam, K. A. Fox, and D. E. Newby Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers smoking, thrombin, and vascular responses in vivo. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Guthmundsdottir, N. N. Lang, N. A. Boon, C. A. Ludlam, D. J. Webb, K. A. Fox, and D. E. Newby Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1749 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pretorius, G. P. van Guilder, R. J. Guzman, J. M. Luther, and N. J. Brown 17{beta}-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women Hypertension, April 1, 2008; 51(4): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Wadsworth Oxidative stress and the endothelium Exp Physiol, January 1, 2008; 93(1): 155 - 157. [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Robinson, C. A. Ludlam, N. A. Boon, and D. E. Newby Endothelial Fibrinolytic Capacity Predicts Future Adverse Cardiovascular Events in Patients With Coronary Heart Disease Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1651 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barac, U. Campia, and J. A. Panza Methods for Evaluating Endothelial Function in Humans Hypertension, April 1, 2007; 49(4): 748 - 760. [Full Text] [PDF]
|
|
|
|
|
|
C. Giannarelli, F. De Negri, A. Virdis, L. Ghiadoni, A. Cipriano, A. Magagna, S. Taddei, and A. Salvetti Nitric Oxide Modulates Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients Hypertension, April 1, 2007; 49(4): 878 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown Blood Pressure Reduction and Tissue-Type Plasminogen Activator Release Hypertension, April 1, 2006; 47(4): 648 - 649. [Full Text] [PDF]
|
|